Primary source: Download the Final Guidance Document
The FDA has released new guidance for premarket notification (510(k)) submissions specifically for dental curing lights, replacing the previous guidance issued in March 2006.
Compliance with this new guidance is critical for manufacturers to ensure their dental curing light devices meet FDA standards, which facilitates smoother regulatory processes and potentially faster market access.
Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.
Issued on September 1, 2026, this guidance document outlines the FDA's recommendations for device description, performance testing, and labeling for premarket submissions of dental curing lights. It is a significant update that supersedes guidance from March 27, 2006, aimed at promoting consistency and efficiency in submission reviews.
What changed: The FDA has released new guidance for premarket notification (510(k)) submissions specifically for dental curing lights, replacing the previous guidance issued in March 2006.
Why it matters: Compliance with this new guidance is critical for manufacturers to ensure their dental curing light devices meet FDA standards, which facilitates smoother regulatory processes and potentially faster market access.
Practical implication: Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.
Published from the regulator source ingestion pipeline after PV impact triage.
Ensure compliance with the updated reference list and adjust internal regulatory monitoring processes to align with the inclusion of new biologicals.
Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.
Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.
Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.
